EQL PHARMA AB (7JK) — Cash Flow Quality Index
EQL PHARMA AB (7JK) has a Cash Flow Quality Index of 1.37x as of December 2025. Operating cash flow of €13.44 Million exceeds net income of €9.79 Million, indicating high earnings quality where cash backs reported profits. Also explore balance sheet size of EQL PHARMA AB for the complete picture of this company's asset base.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
EQL PHARMA AB Cash Flow Quality Index (2022–2025)
Historical Cash Flow Quality Index for EQL PHARMA AB across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check tangible net worth ratio of EQL PHARMA AB to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for EQL PHARMA AB (2022–2025)
Year-by-year earnings quality comparison for EQL PHARMA AB. For live market cap and the full company financial profile, see EQL PHARMA AB (7JK) market capitalisation.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | -0.57x | €-24.65 Million | €43.12 Million | ▼ -13.5% |
| 2024 | -0.50x | €-11.44 Million | €22.70 Million | ▼ -156.4% |
| 2023 | 0.89x | €27.62 Million | €30.92 Million | ▼ -32.6% |
| 2022 | 1.33x | €41.83 Million | €31.55 Million | — |